Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.84 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799237 | 0.92 | MAPK1 (1.00) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL20110189 | 0.90 | KDM4E (0.78) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL20110178 | 0.87 | MAPK1 (0.85) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL21990726 | 0.86 | MAPK1 (0.89) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL22060123 | 0.85 | MAPK1 (0.82) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL20110265 | 0.84 | MAPK1 (0.85) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL22060371 | 0.84 | MAPK1 (0.84) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL20110209 | 0.84 | MAPK1 (0.84) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL19668521 | 0.84 | MAPK1 (0.80) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 | |
| SCHEMBL20110191 | 0.84 | MAPK1 (0.79) | MAPK1CDKN1ALMNASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118697-A1 | TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | PINK1, ATG7, ADRM1 | MAPK1 2124/4885CDKN1A 356/4885LMNA 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.